News Release

Patent "System for Extracting Tetrodotoxin" issued by USPTO

Date: Nov 13, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that the United States Patent and Trademark Office (USPTO) has officially issued to the Company a patent under the title of "System for Extracting Tetrodotoxin".

This patent covers the system for extracting TTX from biological tissues. More importantly, the system enables us to produce TTX not only with high yield but at a commercially viable scale. Since the drug products which the Company is developing address the needs of millions of patients in the world, the manufacturing technologies for TTX as the major drug substance have been made ready and protected. This patent also complements the other two patents which the Company owns for the treatment of drug addiction and pain management. To date the Company has eight more patent applications pending and numerous others to be filed in connection to its TTX platform technology, among other things. The Company will continue to build up its intellectual properties and obtain protection world wide.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.